Avacta Group (AVCT) Status Update summary

Key scientific findings and clinical updates

• AVA6000 demonstrated a strong safety profile, with significantly reduced bone marrow and cardiac toxicities compared to conventional doxorubicin, and no maximum tolerated dose identified up to 385 mg/m².

• Disease control rate in metastatic salivary gland cancer reached over 90%, with a median progression-free survival of 5.9 months, nearly doubling the historical benchmark.

• AVA6000 achieves high tumor drug concentration with minimal normal tissue exposure, supporting the precision platform's mechanism and potential for improved patient outcomes.

• AVA6103, a FAP-exatecan conjugate, showed potent and durable anti-tumor responses in preclinical models, with extended tumor drug exposure and favorable safety in animals.

• AVA6103 is advancing toward clinical trials, with IND submission planned for year-end and first-in-human studies expected in the first quarter of next year.

Strategic and pipeline developments

• Expansion cohorts for AVA6000 are enrolling in three disease settings, with key data readouts expected later this year and early next year.

• AVA6103 will enter clinical development in early next year, with patient selection guided by AI-driven analysis of the Tempus database to identify FAP-expressing, TOPO1-sensitive tumors.

• The company is also developing additional warheads, with new IP filed for a sustained release mechanism, and expects further pipeline expansion over the next two years.

• Business development strategy includes seeking partners for AVA6000 as it moves into later-stage trials, and considering partnerships for AVA6103 after clinical data is available.

• The Tempus collaboration provides access to a large, well-annotated dataset, enabling efficient trial design and patient population selection without commercial rights for Tempus.

Risk assessment and future outlook

• Key risks for AVA6000 include transitioning from phase I to later-stage trials, enrolling appropriate patient populations, and outperforming standard of care in comparator arms.

• Expansion cohorts are designed to refine patient selection and de-risk subsequent trial phases, with ongoing efforts to optimize trial design and statistical power.

• AVA6103's preclinical safety and efficacy are promising, with translational and preclinical data supporting its advancement, though challenges remain in translating results to humans.

• Timelines for AVA6000 include final phase I dose escalation data later this year, salivary gland expansion data late this year, and breast cancer data early next year.

• IND submission for AVA6103 is planned for year-end, with clinical trials to begin in the first quarter of next year.